Photo of Alexander Melamed,  MD, MPH

Alexander Melamed, MD, MPH

Massachusetts General Hospital

Massachusetts General Hospital

Photo of Alexander Melamed,  MD, MPH

Massachusetts General Hospital

Visualize Collaborations

Alexander Melamed, MD, MPH

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Associate Professor, Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School
  • Assistant in Gynecology and Obstetrics, Obstetrics and Gynecology, Massachusetts General Hospital

HCC PROGRAM AFFILIATION

Research Abstract

I am interested in harnessing existing sources of data to improve the care of patients with gynecologic cancers, by providing credible evidence about the most effective and individualized care.

The treatment that a cancer patient receives is influenced by prediagnosis characteristics, disease factors, and provider attributes that may also affect the outcomes being studied. When enough confounders have been measured, it may be possible to accurately estimate causal associations between treatments and outcomes using a classical epidemiological approach. Unfortunately, it is common that the available data is missing information about important confounders. Unmeasured (and unmeasurable) confounding is a central threat to the validity of causal claims about cancer treatments when such claims are based on analyses of observational data.​

In my observational research, I use analytical approaches that can, sometimes, overcome unmeasured confounding by identifying natural experiments in cancer care delivery. Specifically, I am interested in how focusing on the variability of treatments across time, space, and provider can help to estimates treatment effects, and overcome treatment selection bias.​

I use methods like difference-in-differences, instrumental variables analysis, interrupted time series, and regression discontinuity designs to generate evidence about the causal effects of cancer treatments on survival, treatment-related toxicity, and medical costs. As a surgeon, I am especially interested in studying the effect of surgical care on cancer outcomes. ​

By generating credible clinical evidence from observational cancer data, I seek to help patients and oncologists make better and more informed treatment decisions.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Melamed A, Eisenhauer EL. Minimally invasive interval cytoreductive surgery for advanced ovarian cancer. J Surg Oncol 2024; 129:126-127. PubMed
  • Jorgensen K, Denham C, Kanbergs A, Wu CF, Nitecki R, Agusti N, Meernik C, Melamed A, Rauh-Hain JA. All-cause and cancer-specific mortality after fertility-sparing surgery for stage IA and IC epithelial ovarian cancer. Gynecol Oncol 2023; 178:60-68. PubMed
  • Agustí N, Viveros-Carreño D, Mora-Soto N, Ramírez PT, Rauh-Hain A, Wu CF, Rodríguez J, Grillo-Ardila CF, Salazar C, Jorgensen K, Segarra-Vidal B, Chacón E, Melamed A, Pareja R. Diagnostic accuracy of sentinel lymph node frozen section analysis in patients with early-stage cervical cancer: A systematic review and meta-analysis. Gynecol Oncol 2023; 177:157-164. PubMed
  • Silberman JN, Bercow AS, Gockley AA, Eisenhauer EL, Sisodia R, Randall T, Del Carmen MG, Goodman A, Castro CM, Melamed A, Bregar AJ. Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States. Gynecol Oncol 2023; 175:60-65. PubMed
  • Abel MK, Myers EL, Minkin E, Tahir P, Haynes AB, Wright JD, Rauh-Hain JA, Melamed A. Cancer-directed surgery in patients with metastatic cancer: A systematic review and meta-analysis of randomized evidence. Cancer Med 2023. PubMed
  • Jorgensen K, Melamed A, Wu CF, Nitecki R, Pareja R, Fagotti A, Schorge JO, Ramirez PT, Rauh-Hain JA. Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy. Gynecol Oncol 2023; 172:130-137. PubMed
  • Suzuki Y, Chen L, Hou JY, St Clair CM, Khoury-Collado F, de Meritens AB, Matsuo K, Melamed A, Hershman DL, Wright JD. Systemic Progestins and Progestin-Releasing Intrauterine Device Therapy for Premenopausal Patients With Endometrial Intraepithelial Neoplasia. Obstet Gynecol 2023; 141:979-987. PubMed
  • Bercow AS, Rauh-Hain JA, Melamed A, Mazina V, Growdon WB, Del Carmen MG, Goodman A, Bouberhan S, Randall T, Sisodia R, Bregar A, Eisenhauer EL, Minami C, Molina G. Association of hospital-level factors with utilization of sentinel lymph node biopsy in patients with early-stage vulvar cancer. Gynecol Oncol 2022; 169:47-54. PubMed
  • Melamed A, Lin YL, Hassan AM, Rauh-Hain JA, Herring B, Keating NL, Offodile AC. Trends in Episode-of-Care Spending for Cancer-Directed Surgery Among US Medicare Beneficiaries From 2011 to 2019. JAMA Surg 2022. PubMed
  • Nitecki R, Melamed A. Extra cycles of neoadjuvant chemotherapy before interval surgery for ovarian cancer: the more the merrier or too much of a good thing? Int J Gynecol Cancer 2022. PubMed
  • Cham S, Li A, Rauh-Hain JA, Tergas AI, Hershman DL, Wright JD, Melamed A. Association Between Neighborhood Socioeconomic Inequality and Cervical Cancer Incidence Rates in New York City. JAMA Oncol 2022; 8:159-161. PubMed
  • Melamed A, Rauh-Hain JA, Gockley AA, Nitecki R, Ramirez PT, Hershman DL, Keating N, Wright JD. Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer. JAMA Oncol 2021; 7:1782-1790. PubMed
  • Nitecki R, Melamed A, Gockley AA, Floyd J, Krause KJ, Coleman RL, Matulonis UA, Giordano SH, Lu KH, Rauh-Hain JA. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. Gynecol Oncol 2021. PubMed
  • Knisely A, Gamble CR, St Clair CM, Hou JY, Khoury-Collado F, Gockley AA, Wright JD, Melamed A. The Role of Minimally Invasive Surgery in the Care of Women with Ovarian Cancer: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol 2021; 28:537-543. PubMed
  • Nitecki R, Melamed A. Time to accept a new old standard of care in cervical cancer. Int J Gynecol Cancer 2020; 30:1278-1279. PubMed
  • Nitecki R, Rauh-Hain JA, Melamed A, Scambia G, Pareja R, Coleman RL, Ramirez PT, Fagotti A. Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE). Int J Gynecol Cancer 2020; 30:1450-1454. PubMed
  • Emeruwa UN, Ona S, Shaman JL, Turitz A, Wright JD, Gyamfi-Bannerman C, Melamed A. Associations Between Built Environment, Neighborhood Socioeconomic Status, and SARS-CoV-2 Infection Among Pregnant Women in New York City. JAMA 2020; 324:390-392. PubMed
  • Nitecki R, Ramirez PT, Frumovitz M, Krause KJ, Tergas AI, Wright JD, Rauh-Hain JA, Melamed A. Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer: A Systematic Review and Meta-analysis. JAMA Oncol 2020; 6:1019-1027. PubMed
  • Melamed A, Bercow AS, Bunnell K, Rauh-Hain JA, Wright JD, Rice LW, Del Carmen MG. Age-Associated Risk of 90-Day Postoperative Mortality After Cytoreductive Surgery for Advanced Ovarian Cancer. JAMA Surg 2019. PubMed
  • Melamed A, Rauh-Hain JA. Minimally invasive interval cytoreductive surgery: it's time for a randomized trial. Int J Gynecol Cancer 2019; 29:1339-1340. PubMed
  • Melamed A, Robinson JN. Case-control studies can be useful but have many limitations: Study design: case-control studies. BJOG 2019; 126:23. PubMed
  • Moss HA, Melamed A, Wright JD. Measuring cause-and-effect relationships without randomized clinical trials: Quasi-experimental methods for gynecologic oncology research. Gynecol Oncol 2019; 152:533-539. PubMed
  • Melamed A, Robinson JN. A study design to identify associations: Study design: observational cohort studies. BJOG 2018; 125:1776. PubMed
  • Melamed A, Fink G, Wright AA, Keating NL, Gockley AA, Del Carmen MG, Schorge JO, Rauh-Hain JA. Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study. BMJ 2018; 360:j5463. PubMed
  • Melamed A, Margul DJ, Chen L, Keating NL, Del Carmen MG, Yang J, Seagle BL, Alexander A, Barber EL, Rice LW, Wright JD, Kocherginsky M, Shahabi S, Rauh-Hain JA. Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. N Engl J Med 2018; 379:1905-1914. PubMed
  • Melamed A, Manning-Geist B, Bregar AJ, Diver EJ, Goodman A, Del Carmen MG, Schorge JO, Rauh-Hain JA. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecol Oncol 2017. PubMed
  • Melamed A, Rizzo AE, Nitecki R, Gockley AA, Bregar AJ, Schorge JO, Del Carmen MG, Rauh-Hain JA. All-Cause Mortality After Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer. Obstet Gynecol 2017; 130:71-79. PubMed
  • Melamed A, Nitecki R, Boruta DM, Del Carmen MG, Clark RM, Growdon WB, Goodman A, Schorge JO, Rauh-Hain JA. Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy. Obstet Gynecol 2017. PubMed
  • Rauh-Hain JA, Melamed A, Wright A, Gockley A, Clemmer JT, Schorge JO, Del Carmen MG, Keating NL. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database. JAMA Oncol 2017; 3:76-82. PubMed
  • Melamed A, Gockley AA, Joseph NT, Sun SY, Clapp MA, Goldstein DP, Berkowitz RS, Horowitz NS. Effect of race/ethnicity on risk of complete and partial molar pregnancy after adjustment for age. Gynecol Oncol 2016; 143:73-6. PubMed
  • Melamed A, Hinchcliff EM, Clemmer JT, Bregar AJ, Uppal S, Bostock I, Schorge JO, Del Carmen MG, Rauh-Hain JA. Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States. Gynecol Oncol 2016. PubMed
  • Melamed A, Keating NL, Clemmer JT, Bregar AJ, Wright JD, Boruta DM, Schorge JO, Del Carmen MG, Rauh-Hain JA. Laparoscopic staging for apparent stage I epithelial ovarian cancer. Am J Obstet Gynecol 2016. PubMed
  • Melamed A, Rauh-Hain JA, Clemmer JT, Diver EJ, Hall TR, Clark RM, Uppal S, Goodman A, Boruta DM. Changing Trends in Lymphadenectomy for Endometrioid Adenocarcinoma of the Endometrium. Obstet Gynecol 2015; 126:815-22. PubMed
  • Melamed A, Katz Eriksen JL, Hinchcliff EM, Worley MJ, Berkowitz RS, Horowitz NS, Muto MG, Urman RD, Feltmate CM. Same-Day Discharge After Laparoscopic Hysterectomy for Endometrial Cancer. Ann Surg Oncol 2015. PubMed
  • Melamed A, Sorvillo FJ. The burden of sepsis-associated mortality in the United States from 1999 to 2005: an analysis of multiple-cause-of-death data. Crit Care 2009; 13:R28. PubMed
Hide